跳至主要内容
临床试验/NL-OMON29150
NL-OMON29150招募中不适用

Safety and clinical performance of the GEM-power Cable system in adult spinal deformity surgery

MaastrichtUMC+0 个研究点目标入组 14 人开始时间: 待定最近更新:

试验速览

阶段
不适用
状态
招募中
发起方
入组人数
14

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

入选标准

  • Signed and dated written informed consent prior to admission to the clinical investigation in accordance with good clinical practice (GCP) and local legislation
  • Male or non-pregnant females
  • > 50 years of age
  • Adult spinal deformity determined as an abnormality of spinal alignment in the axial, coronal or sagittal plane [1], amenable for surgical treatment
  • Planned surgical instrumented spinal fusion of > 4 levels (> 5 vertebrae)
  • Body Mass Index index (BMI) < 40 kg/m2

排除标准

  • Patients with metal allergy/intolerance
  • Patients with compromised anatomical integrity of the laminar arch or a previous spinal surgery which may have compromised the integrity of the laminar arch (i.e. laminectomy) at proximal construct levels.
  • Previous spinal deformity correction surgery
  • Patients with any form of kidney dysfunctioning
  • Female patients that are pregnant or plan to become pregnant
  • Patients unwilling to cooperate with the study protocol and follow up schedule
  • Patients judged by the surgeon mentally incapable to follow study requirements
  • Patients with neuromuscular or neuro-sensory deficit which would limit the ability to assess the performance of the device
  • Diagnosed with active malignancy
  • Active alcohol or drugs abuser as defined by currently undergoing treatment for this abuse or as judged by the surgeon is likely to interfere with protocol compliance
  • Known systemic or metabolic disorders leading to progressive bone deterioration except patients with osteoporosis with a T-score of minimal -3.5 (below -3.5 is exclusion)
  • Use of systemic corticosteroids within the last 3 months ( inhaled steroids are no reason for exclusion)
  • presence of an active or suspected infection
  • Chronic disease that compromises the immune system (e.g. known HIV or known hepatitis).
  • Uncontrolled diabetes mellitus as determined by treating physicians
  • Participation in an ongoing investigational drug or device trial that has not completed the follow-up period.

研究者

发起方
MaastrichtUMC+

相似试验